Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping : an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, and clinical reporting for laboratories, as well as emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretells a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Journal of clinical microbiology - 60(2022), 1 vom: 19. Jan., Seite e0165921 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Greninger, Alexander L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ASM |
|---|
| Anmerkungen: |
Date Completed 25.01.2022 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/JCM.01659-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332691497 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332691497 | ||
| 003 | DE-627 | ||
| 005 | 20231225220102.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/JCM.01659-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332691497 | ||
| 035 | |a (NLM)34731022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Greninger, Alexander L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping |b an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, and clinical reporting for laboratories, as well as emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretells a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ASM | |
| 650 | 4 | |a IDSA | |
| 650 | 4 | |a RT-qPCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a allele specific | |
| 650 | 4 | |a clinical applications | |
| 650 | 4 | |a consensus | |
| 650 | 4 | |a genomics | |
| 650 | 4 | |a genotyping | |
| 650 | 4 | |a sequencing | |
| 700 | 1 | |a Dien Bard, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Colgrove, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a Graf, Erin H |e verfasserin |4 aut | |
| 700 | 1 | |a Hanson, Kimberly E |e verfasserin |4 aut | |
| 700 | 1 | |a Hayden, Mary K |e verfasserin |4 aut | |
| 700 | 1 | |a Humphries, Romney M |e verfasserin |4 aut | |
| 700 | 1 | |a Lowe, Christopher F |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Melissa B |e verfasserin |4 aut | |
| 700 | 1 | |a Pillai, Dylan R |e verfasserin |4 aut | |
| 700 | 1 | |a Rhoads, Daniel D |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Joseph D |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Francesca M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical microbiology |d 1975 |g 60(2022), 1 vom: 19. Jan., Seite e0165921 |w (DE-627)NLM000005460 |x 1098-660X |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2022 |g number:1 |g day:19 |g month:01 |g pages:e0165921 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/JCM.01659-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2022 |e 1 |b 19 |c 01 |h e0165921 | ||